Skip to content

Speakers

Expand/Collapse

Dominic Chiapperino
Director of Controlled Substances Staff
U.S. Food and Drug Administration

Dr. Chiapperino is the Director of the Controlled Substance Staff (CSS), a group with expertise in the assessment of the abuse potential of drugs.  He has worked extensively on FDA policy and regulatory issues involving cannabis and related substances and, prior to CSS, was with CDER’s Division of Anesthesia, Analgesia, and Addiction Products gaining regulatory experience concerning opioids analgesics and drugs indicated for the treatment of substance use disorders.  He received his PhD in organic chemistry from the University of Maryland in 2000 and did post-doctoral research with the National Institute of Diabetes and Digestive and Kidney Diseases before beginning his career at FDA in 2002.

Day One

Wednesday September 11 2019

8:30 am | FDA Regulatory Roles Concerning Cannabis and New Drug Research

Barbara White
Chief Medical Officer and Head, Research
Corbus Pharmaceuticals

Barbara White provides overall leadership for clinical development and pre-clinical research at Corbus. Barbara’s industry experience includes Phase 1-4 clinical development, pre-clinical drug development, translational medicine, personalized medicine, and medical affairs. Prior to her work at Corbus, Barbara was senior vice president and head of R&D for Stiefel, a GSK company that focused on medications and consumer products in dermatology. She has held prior roles as head of clinical development in Inflammation in UCB and in Inflammation, Autoimmunity, and Respiratory at MedImmune/ AstraZeneca. Barbara began her career in industry in Medical Affairs at Amgen.

Day Two

Thursday September 12 2019

4:00 pm | Targeting the Endocannabinoid System to Develop Medicines to Treat Inflammatory and Fibrotic Diseases

Guy Chamberland
Chief Executive Officer
Tetra Biopharma

Day One

Wednesday September 11 2019

12:15 pm | Panel Discussion: Whole Plant Vs. Synthetic Cannabinoids and Their Relative Potential in Pharmaceuticals

Day Two

Thursday September 12 2019

2:00 pm | Pain & Opioids – How are Cannabinoids Playing a Role in Both Pain Relief & Addiction?

Dennis Ahern
Vice President - Global Regulatory Affairs
Greenwich Biosciences

Day One

Wednesday September 11 2019

9:45 am | Industry Perspective on the Regulatory Approval Pathway

Mara Gordon
Founder & Director
Zelda Therapeutics

Mara specializes in the development of cannabis treatment protocols for seriously ill patients, and is a pioneer in medicinal cannabis. She is the founder of Aunt Zelda’s™, Chief Research Officer of GABY, and co-founder of its subsidiary, The Oil Plant (TOP). She is a Director of multiple companies in the US, Canada, and Australia, including Zelda Therapeutics. Her work is highlighted in the award-winning documentaries, Weed the People and Mary Janes: Women of Weed.

Day One

Wednesday September 11 2019

12:15 pm | Panel Discussion: Whole Plant Vs. Synthetic Cannabinoids and Their Relative Potential in Pharmaceuticals

Day Two

Thursday September 12 2019

1:30 pm | Comparison of the Anti-Tumor Efficacy of A Whole-Plant Extract Vs. Pure THC in Preclinical Models of HER2-Positive Breast Cancer

Brian Murphy
Chief Executive Officer
Emerald Bioscience Inc.

Day One

Wednesday September 11 2019

6:00 pm | Chair’s Closing Remarks

8:20 am | Chair’s Opening Remarks

Day Two

Thursday September 12 2019

4:30 pm | Chair’s Closing Remarks

11:00 am | The Therapeutic Potential of Cannabinoids in Ocular Disease: The EMBI Experience

8:20 am | Chair’s Opening Remarks

Sara Ward
Researcher – Oncology
Temple University

Dr. Ward’s research interests focus on the therapeutic potential of non-psychoactive cannabinoid compounds for the treatment of nervous system disorders, including neuropathic pain, neuroinflammation, and substance abuse. There are two ongoing projects investigating cannabinoid effects on neuropathic pain. The goal of these projects is to elucidate the therapeutic mechanisms by which the non-psychoactive cannabinoid, cannabidiol, protects against the development of neuropathic pain. Dr. Ward’s laboratory uses two mouse models of neuropathic pain 1) a central model of spinal cord injury and 2) a peripheral model of chemotherapy-induced neuropathic pain. The therapeutic strategy includes understanding the neuroprotective mechanisms of cannabidiol alone and in combination with the psychoactive phytocannabinoid, D9-tetrahydrocannabinol (D9-THC) and other minor phytocannabinoids.

Ethan Russo
Professor
International Cannabis and Cannabinoids Institute

ICCI - International Cannabis and Cannabinoids Institute

Day One

Wednesday September 11 2019

3:00 pm | Panel Discussion: Summarizing the Advances in Cannabinoid Pharmacology and ECS Targeting

2:30 pm | The Importance of Understanding the ECS in Drug Design & Formulation

Andrea Small-Howard
Chief Science Officer
GB Sciences

Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc. Dr. Small-Howard has more than 15 years’ experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration ("US FDA") and multiple international regulatory agencies, and has assisted state jurisdictions in developing medical cannabis regulations. She brings to GB Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline, and a track record of successes in the management of biopharmaceutical companies.   Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All-University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor. Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements. For a four year term, she served on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.

Day Two

Thursday September 12 2019

9:00 am | Unique Methods to Identify Strong Lead Compounds

Robert Walsh
Chief OF Regulatory Affairs Branch NIH / NIDA
Division of Therapeutics & Medical Consequences of Drug Abuse
NIDA

Day One

Wednesday September 11 2019

9:15 am | NIDA Perspective on Cannabinoid Pharmaceuticals

Sagnik Bhattacharyya
Reader of Translational Neuroscience & Psychiatry
King’s College London

Day Two

Thursday September 12 2019

11:30 am | Cannabinoids for Neuropsychiatric Disorders: Focus on Cannabidiol

George Annasstasov
Chief Executive Officer
Axim Biotech

Day Two

Thursday September 12 2019

8:30 am | Improving the Bioavailability of Cannabinoids

Loren DeFalco
Partner
CB1 Capital

Day One

Wednesday September 11 2019

5:30 pm | Panel Discussion: The Investor’s Perspective on the Cannabinoid Pharmaceuticals Field

Michael Woudenburg
Vice President, Chemistry,
Manufacturing and Control (CMC)
InMed Pharmaceuticals

Mr. Woudenberg leads all aspects of CMC at InMed.  He brings over 20 years of engineering leadership and GMP manufacturing and scale-up experience in the development, technology transfer and commercialization of active pharmaceutical ingredients (APIs), including process and formulation development from lab scale through clinical development to validated and successfully approved commercial APIs. He has extensive experience with regulatory inspections (FDA, EMEA, Health Canada, etc.) and related CMC requirements from clinical to commercial production of approved products.  Mr. Woudenberg held various positions with Cardiome, Arbutus Biopharma and as Managing Director of Phyton Biotech. Mr. Woudenberg received his Bachelor’s in Chemistry and Bachelor’s of Chemical Engineering at Western University of London, Ontario, Canada.

Day One

Wednesday September 11 2019

12:15 pm | Panel Discussion: Whole Plant Vs. Synthetic Cannabinoids and Their Relative Potential in Pharmaceuticals

Josh Blacher
Chief Financial Officer
InMed Pharmaceuticals

Mr. Blacher two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with the investment community. Before joining InMed, Mr. Blacher served as Chief Financial Officer at the cannabinoids company Therapix Biosciences and at Galmed Pharmaceuticals. Mr. Blacher also held senior positions in-licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in Mergers & Acquisitions at Lehman Brothers.  Mr. Blacher holds an MBA in Finance from Columbia Business School.

Day One

Wednesday September 11 2019

5:30 pm | Panel Discussion: The Investor’s Perspective on the Cannabinoid Pharmaceuticals Field

Eric Hsu
Sr. Vice President,
Preclinical Research and Development
InMed Pharmaceuticals

Dr. Hsu is responsible for InMed’s preclinical drug development pipeline and pre-commercial R&D for InMed’s proprietary biosynthesis platform technology.  He brings over 20 years of scientific leadership experience in the field of gene-based research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships.  He received his Doctorate from the Department of Medical Biophysics at University of Toronto and his Bachelor’s degree from McGill University.

Day One

Wednesday September 11 2019

5:00 pm | Panel Discussion: The Potential Effects Biosynthesis Could Have on the Cannabinoid-Derived Pharmaceuticals Development Process and the Wider Industry

Vincenzo di Marzo
Director
Joint International Research Unit UMIMicroMeNu

Dr. Vincenzo Di Marzo is Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (MEND) at Laval University, Quebec, Canada, and Research Director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Naples, Italy. He is also the coordinator of the Endocannabinoid Research Group (www.icb.cnr.it/erg) in the Naples region, and the director of the Joint International Research Unit between the Italian National Research Council and Université Laval, for Chemical and Biomolecular Research on the Microbiome and its impact on Metabolic Health and Nutrition (MicroMeNu, www.umilaval.cnr.it). He holds a ChemD from the University of Naples in 1983, and a PhD in Biochemistry from Imperial College in London in 1988. He is co-author of over 670 articles published in peer-reviewed journals (H index 117 according to Scopus).   In 2014- 2017 he has been listed among the Highly Cited Researchers (top 1% in the world) in all scientific disciplines (www.highlycited.com; http://hcr.stateofinnovation.com/). He has been the recipient of numerous research grants and awards, including: a Human Frontier Science Program research grant to study the biosynthesis, metabolism, and structure-activity relationships of anandamide; a Merkator Fellowship for Foreign Scientists by the Deutsche Forschungsgemeinshaft; the Mechoulam Award for “his outstanding contributions to cannabinoid research”; the Luigi Tartufari award for Chemistry from the Italian Academy of Sciences (Accademia dei Lincei); the “Ester Fride Award for Basic Science” from the International Association for Cannabinoid Medicines. In October 2014 he was awarded the International Award “Guido Dorso” for Research, and in May 2016 the Medal of the Italian Accademia delle Scienze, or of the XL, for Physical and Natural Sciences. In November 2018 he will be elected member of the Italian Accademia dei Lincei, the oldest science academy in the world.

Day One

Wednesday September 11 2019

3:00 pm | Panel Discussion: Summarizing the Advances in Cannabinoid Pharmacology and ECS Targeting

2:00 pm | Updates on the Pharmacology of Low Weight Cannabinoids

Matt Callahan
Executive Chairman
Botanix Pharmaceuticals

Day Two

Thursday September 12 2019

3:00 pm | Cannabinoids in Dermatology – Sorting Fact From Fiction

Josh Hoerner
Managing Director & Senior Director,
Innovation & Product Development
Noramco Inc.

Day One

Wednesday September 11 2019

11:45 am | The New Era of Ultra-Pure Pharmaceutical Cannabinoids: CBD, THC, and Beyond

Michael Freeman
Associate
Raymond James

Day One

Wednesday September 11 2019

5:00 pm | Panel Discussion: The Potential Effects Biosynthesis Could Have on the Cannabinoid-Derived Pharmaceuticals Development Process and the Wider Industry

Rahul Sarungaser
Analyst
Raymond James

Day One

Wednesday September 11 2019

4:30 pm | Cannabinoid Biosynthesis: Engineering the Most Disruptive Technology in the Cannabis Industry

Jeff Margolis
Senior Vice President, Treasurer
Secretary & Chief Financial Officer
RespireRx Pharmaceuticals

Mr. Margolis has been an executive officer and BOD member of RespireRx since March 2013. Mr. Margolis has also served as President of Aurora Capital LLC, a boutique investment bank and securities firm specializing in the life science sector, since he founded its predecessor company, Aurora Capital Corp. in 1994.

Day One

Wednesday September 11 2019

5:30 pm | Panel Discussion: The Investor’s Perspective on the Cannabinoid Pharmaceuticals Field

Robert Brooke
Chief Executive Officer & Co-Founder,
Director - Scientific Research & Development & Co- Founder
Vitality Biopharma

Day Two

Thursday September 12 2019

3:30 pm | VBX-100: A GI-targeted Prodrug of THC for Inflammatory Bowel Disease

Brandon Zipp
Director - Scientific Research & Development & Co- Founder
Vitality Biopharma

Dr. Brandon Zipp is the Director of Research & Development and a Scientific Co-founder of Vitality Biopharma, Inc. He is a developer and inventor of the company’s cannaboside compounds, a class of cannabinoid derivatives produced by enzymatic glycosylation, which improves solubility while targeting cannabinoid release in the gastrointestinal tract. He has diverse training in plant secondary metabolism, colorectal cancer, and fermentation, combined with extensive laboratory experience with glycosyltransferases, the class of enzymes that enable production of cannabosides. Dr. Zipp earned his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis in 2013.

Day One

Wednesday September 11 2019

5:00 pm | Panel Discussion: The Potential Effects Biosynthesis Could Have on the Cannabinoid-Derived Pharmaceuticals Development Process and the Wider Industry

Haleli Sharir
Principal Scientist
Cannabics Pharmaceuticals

Dr. Sharir received her PhD degree in Cell Biology and was one of the first to test the assignment of GPR55 as a third cannabinoid receptor. At Cannabics, she has implemented AI and drug screening tools to create cannabinoid based therapies for cancer. Dr. Sharir talked with me about the stigma of cannabis, the science driving innovation and the goals of Cannabics going forward.

Day Two

Thursday September 12 2019

9:30 am | Advancing Personalized Therapies using Cannabinoid APIs

Alex Makriyannis
George D. Behrakis Chair in Pharmaceutical Biotechnology Director, Center for Drug Discovery
Northeastern University